CME Presentations

TK2 Deficiency Disorder


Presentations


Speakers

  • Colleen Muraresku, MS, LCGC

    Colleen Muraresku, MS, LCGC

    Colleen Muraresku, MS, LCGC

    Senior Genetic Counselor & Program Director

    Colleen Clarke Muraresku, MS, LCGC, is a licensed genetic counselor, program director for the Mitochondrial Medicine Frontier Program, and co-chair for the Research Committee for the Section of Genetic Counseling at The Children’s Hospital of Philadelphia (CHOP) in Pennsylvania. During the span of her career, she has focused on metabolic disorders with a special interest in mitochondrial disease. Colleen helped launch the first clinical trial in mitochondrial disease at CHOP. She has since participated in numerous clinical trials and has published more than a dozen peer-reviewed articles. Colleen is certified by the American Board of Genetic Counseling and is an active member of the Mitochondrial Medicine Society and the United Mitochondrial Disease Foundation.
  • Michio Hirano, MD

    Michio Hirano, MD

    Michio Hirano, MD

    Lucy G. Moses Professor of Neurology

    Michio Hirano, MD, is the Lucy G. Moses Professor of Neurology, director of the H. Houston Merritt Clinical Research Center, and chief of the Division of Neuromuscular Medicine at Columbia University Irving Medical Center in New York City. For more than 25 years, Dr Hirano’s translational research has focused on mitochondrial disease and inherited myopathies. His laboratory has identified the causative genes for multiple inherited diseases. Dr Hirano received his medical degree from the Albert Einstein College of Medicine in the Bronx, New York. After completing neurology residency at the Neurological Institute of New York, he did a post-doctoral fellowship in neuromuscular genetics at the H. Houston Merritt Clinical Research Center.
  • Marni Falk, MD

    Marni Falk, MD

    Marni Falk, MD

    Executive Director of the Mitochondrial Medicine Frontier Program

    Marni J. Falk, MD, is executive director of the Mitochondrial Medicine Frontier Program at The Children's Hospital of Philadelphia (CHOP), clinical geneticist, and professor in the Division of Human Genetics within the Department of Pediatrics at the University of Pennsylvania (UPENN) Perelman School of Medicine in Pennsylvania. She works to improve precision clinical care, diagnostic approaches, and genomic resources for mitochondrial disease. Dr Falk has authored more than 125 peer-reviewed publications in the areas of human genetics and mitochondrial disease. She directs the CHOP/UPENN Mitochondria Research Affinity Group that has 75 participants and is a founding member of the CHOP Center for Mitochondrial and Epigenomic Medicine (CMEM).

CME Information

Progressive Myopathy: Could it be a Genetic Mitochondrial Disease?


PIM Logo PQH Logo

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:
  • Demonstrate an enhanced index of suspicion for the diagnosis of a genetic mitochondrial disease in infants, children, and adults who present with progressive muscle weakness
  • Describe the diagnostic work-up for a patient with mitochondrial disease and how to utilize genetic testing as part of the diagnostic approach
  • Describe key manifestations of thymidine kinase 2 (TK2) deficiency across the spectrum of disease severity and age as an example of mitochondrial DNA replication deficiency syndrome (MDS)
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the National Organization for Rare Disorders (NORD) and the United Mitochondrial Disease Foundation (UMDF).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Zogenix.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Friday, March 19, 2021 from 11:00am – 12:00noon ET

Enduring Material

The enduring material will be available from March 19, 2021 to March 19, 2022.

TARGET AUDIENCE

The intended audience for this activity are pediatric neurologists, neurologists, pediatricians, neuromuscular specialists, primary care providers, pulmonologists, gastroenterologists, advanced practice providers (NPs, PAs), physical therapists/occupational therapists, nutritionists, and geneticists.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Michio Hirano, MD
Lucy G. Moses Professor of Neurology
Chief, Neuromuscular Medicine Division
Director, H. Houston Merritt Neuromuscular Research Center
Columbia University Irving Medical Center
Vagelos College of Physicians and Surgeons
Royalty: Modis Therapeutics
Receipt of Intellectual Property Rights/Patent Holder: Modis Therapeutics
Consulting Fees (e.g., advisory boards): Entrada Therapeutics, Modis Therapeutics
Contracted Research: Entrada Therapeutics, Steath Therapeutics
Marni J. Falk, MD
Professor, Division of Human Genetics, Department of Pediatrics
Executive Director, Mitochondrial Medicine Frontier Program
Children’s Hospital of Philadelphia
University of Pennsylvania Perelman School of Medicine
Royalty: Elsevier
Receipt of Intellectual Property Rights/Patent Holder: Children’s Hospital of Philadelphia
Consulting Fees (e.g., advisory boards):
Zogenix, Inc., LarimarTherpaeutics, Khondrion, Imel Therapeutics, Minovia Therapeutics, Stealth BioTherapeutics, Casma Therapeutics, Astellas, Epirium Bio, Cyclerion Therapeutics, NeuroVive Therapeutics
Contracted Research: AADI Therapeutics, Cardero Therapeutics, Cyclerion Therapeutics, Epirium Bio, Imel Therapeutics, Minovia Therapeutics Inc., Mission Therapeutics, NeuroVive, Raptor Therapeutics, REATA Inc., RiboNova Inc., Standigm Therapeutics, Stealth BioTherapeutics
Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): MitoCureia; RiboNova, Inc.
Colleen Clarke Muraresku, MS, LCGC
Senior Genetic Counselor & Program Director
Mitochondrial Medicine Frontier Program
The Children’s Hospital of Philadelphia
Has no financial relationships to report

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 877-394-1306 or at Support@NeuroSeriesLive.com.